(lp0
S"Acorda Therapeutics Higher Off Favorable Patent Ruling Related To Ampyra Benzinga - Mar 9, 2017 Acorda Therapeutics Inc  shares are trading higher by $1.83  at $30.13 in Thursday's session.Acorda Therapeutics up 7% on patent ruling - Seeking AlphaAcorda Therapeutics, Inc.  Files An 8-K Other Events - Market Exclusive"
p1
aS'Equity Watch for Acorda Therapeutics, Inc.  Rives Journal - 6 hours ago Acorda Therapeutics, Inc.  currently has a Gross Margin  ratio of 0.306549. Robert Novy-Marx has provided investors with insights on finding high-quality value stocks.'
p2
aS'Acorda Therapeutics Can Deliver Sustained Growth Seeking Alpha - Aug 24, 2016 Acorda Therapeutics  is a small biotech  that markets three products for patients suffering from the effects of multiple sclerosis , spinal cord injury , stroke, and neuropathic pain .'
p3
aS"Acorda Up, But Patent Battle Looms Seeking Alpha - Feb 13, 2017 Positive phase III results for Acorda's  inhaled levodopa CVT-301 sent the company's stock up 21% yesterday but, with its multiple sclerosis therapy Ampyra facing two patent decisions this quarter, sales of Acorda's biggest earner could ...Acorda Therapeutics, Inc.  could bounce on good earnings data out ... - FinancialsTrendAcorda Provides Financial and Pipeline Update for Fourth Quarter and Year End 2016 - Business Wire "
p4
aS'Stock Returns: Acorda Therapeutics Inc  versus MiMedx Group Inc ... CML News - 17 hours ago This is a snapshot to compare the stock returns for Acorda Therapeutics Inc  versus MiMedx Group Inc  .Checking the Levels on Shares of Acorda Therapeutics, Inc.  - Baldwin JournalLatest Stocks: The State Street Corp Acquires 166936 Shares of Acorda ... - Petro Global News 24'
p5
aS"JP Morgan Provides Thoughts On Acorda Therapeutics Inc  Smarter Analyst - Feb 9, 2017 Acorda Therapeutics Inc  shares rose 13% in Thursday's trading session, after the drug maker announced topline data for CVT-301, an inhaled levodopa therapy for episodic treatment of off episodes in Parkinson's disease, from its Phase 3&nbsp;...Acorda Therapeutics  Phase 3 Trial CVT-30 Shows Statistically ... - StreetInsider.comWhy Acorda Therapeutics Stock Is Jumping Today - Motley Fool"
p6
aS"Equity Perception: Analyst's Indicator Review for AVEO Pharmaceuticals, Inc ... The USA Commerce - Mar 27, 2017 Shares of AVEO Pharmaceuticals, Inc.  dropped -6.24% to $0.67. During the trading on 03/24/2017, Company's stock ranged from $0.71 to $0.61. The relative strength index or RSI highlights overbought  and oversold &nbsp;..."
p7
aS"Acorda Therapeutics plummets as much as 13% on failed trial, discontinued drug ... MarketWatch - Nov 21, 2016 Acorda Therapeutics Inc. shares dropped as much as 13.2% in pre-market trade Monday after the company said it was discontinuing development of its drug intended for post-stroke walking difficulties after a clinical trial failure.Acorda Therapeutics: Punished By A Small Disappointment - Barron's Stock Update : Here's Why Acorda Therapeutics Inc Shares Are ... - Smarter Analyst"
p8
aS'Acorda Therapeutics  Jumps: Stock Adds 6.5% in Session Yahoo Finance - Mar 10, 2017 Acorda Therapeutics, Inc. ACOR was a big mover last session, as its shares rose above 6% on the day. The move came after the United States Patent and Trademark Office  Patent Trials and Appeal Board  upheld all four patents challenged&nbsp;...'
p9
aS"Acorda Therapeutics Has Significant Upside From Its Current Stock Price Seeking Alpha - Jul 7, 2016 Acorda Therapeutics  is a central nervous system  focused emerging biopharmaceutical company. The company's pipeline includes products targeted at areas of unmet need like OFF symptoms of Parkinson's disease ,&nbsp;..."
p10
a.